Evaluation of the Effectiveness of the AggreGuide A-100 in Measuring Platelet Aggregation in Individuals Taking a High or Low Dose of Aspirin

To evaluate the effectiveness of the AggreGuide A-100, a point-of-care platelet aggregometer, in detecting aspirin-induced platelet dysfunction at high and low doses of aspirin. Sixty-five individuals who had not been taking aspirin in the previous 14 days were recruited for the High-Dose Aspirin Study and were administered a single high dose of aspirin (650 mg). Thirteen subjects who had been aspirin-free for 7 to 10 days were subsequently recruited for the Low-Dose Aspirin Study and were administered a low dose of aspirin (81mg/day) for 7 to 10 days. We obtained measurements of the subjects’ whole-blood samples using the AggreGuideA-100 at baseline and after the ingestion of aspirin in both groups. In the High-Dose Aspirin Study, 59 of the 65 subjects (91%) exhibited a reduction in their platelet aggregation index (PAI) value, as measured by the AggreGuide A-100, after taking a single 650 mg dose of aspirin. In the Low-Dose Aspirin Study, all 13 subjects (100%) exhibited a reduction in their PAI value, as measured by the AggreGuide A-100, after taking 81 mg per day of aspirin for 7 to 10 days. The results from the High- and Low-Dose Aspirin Groups indicate that the AggreGuide A-100 yields prompt, reliable measurement of aspirin-induced dysfunction, as indicated by a decreasing PAI value, in the presence of high or low doses of aspirin.